Ophthalmology · Coral Gables, FL
NPI
1023057395
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
1097 S Lejeune Rd
Coral Gables, FL, 33134
Phone (305) 442-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$79K
918 services
Medicare patients, 2024
77
Average age 77
Drug cost, 2024
$3.8M
4,735 prescriptions
Company payments, 2025
$700
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth T Wals was code 92134 (computerized ophthalmic imaging), 126 times for 58 patients. In total Kenneth T Wals billed 918 services in 31 codes, and Medicare paid $79K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-06-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92134 Computerized Ophthalmic Imaging | Office | 126 | 58 | $30.20 | $3,805 |
| 67028 Intravitreal Injection | Office | 77 | 28 | $93.70 | $7,215 |
| 99213 Office E&M - Established | Office | 42 | 29 | $71.84 | $3,017 |
| 92014 Ophthalmological E&M | Office | 38 | 31 | $94.55 | $3,593 |
| J7999 Compounded drug, not otherwise classified | Office | 32 | 17 | $64.56 | $2,066 |
| 92201 Ophthalmological E&M | Office | 26 | 19 | $17.23 | $448 |
| 92202 Ophthalmological E&M | Office | 16 | 14 | $10.19 | $163 |
By year: 2022 $81K for 692 services; 2023 $117K for 773 services; 2024 $79K for 918 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth T Wals prescribed most often to Medicare patients was Eylea (Aflibercept), with 774 prescriptions and refills. In total Kenneth T Wals wrote 4,735 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eylea Aflibercept | 774 | 798 | 168 | $1.7M |
| Prednisolone Acetate Generic | 600 | 743 | 347 | $21K |
| Ilevro Nepafenac | 302 | 465 | 208 | $110K |
| Vabysmo Faricimab-Svoa | 295 | 301 | 58 | $676K |
| Latanoprost Generic | 235 | 339 | 64 | $1,188 |
| Bromfenac Sodium Generic | 217 | 240 | 138 | $13K |
| Moxifloxacin Moxifloxacin Hcl | 182 | 186 | 155 | $5,887 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 171 | 334 | 63 | $1,414 |
| Brimonidine Tartrate Generic | 171 | 309 | 65 | $3,792 |
| Restasis Cyclosporine | 153 | 242 | 50 | $150K |
| Gatifloxacin Generic | 151 | 158 | 114 | $10K |
| Lucentis Ranibizumab | 141 | 141 | 43 | $249K |
| Timolol Maleate Generic | 110 | 188 | 33 | $897 |
| Lumigan Bimatoprost | 105 | 160 | 31 | $43K |
| Syfovre Pegcetacoplan/Pf | 103 | 103 | 14 | $330K |
Brand drugs: 3,304 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth T Wals $700 ($700 in general payments such as food, travel and fees) from 6 companies. The largest payer was Abbvie Inc. with $293.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.